Watari Hidemichi

ワタリヒデミチ | Watari Hidemichi

Affiliation and department：
Homepage URL (1)： http://kaken.nii.ac.jp/d/r/10344508.ja.html

Research field (1)： Obstetrics and gynecology

Research keywords (22)：抗癌剤耐性 , 卵巣癌 , MET , clusterin , 抗がん剤耐性 , micfroRNA , micro RNA , アポトーシス , 子宮体がん , 医学 , 婦人科腫瘍学 , 分子標的治療 , dominant negative , p53がん抑制遺伝子 , p53癌抑制遺伝子 , 遺伝子変異 , 子宮体癌 , 悪性腫瘍 , 浸潤能 , 運動能 , gain-of-function , p53変異

Papers (96)：

Takashi Mitamura, Peixin Dong, Kei Ihira, Masataka Kudo, Hidemichi Watari. Molecular-targeted therapies and precision medicine for endometrial cancer. Japanese journal of clinical oncology. 2019. 49. 2. 108-120
Dong P, Xiong Y, Yu J, Chen L, Tao T, Yi S, Hanley SJB, Yue J, Watari H, Sakuragi N. Control of PD-L1 expression by miR-140/142/340/383 and oncogenic activation of the OCT4-miR-18a pathway in cervical cancer. Oncogene. 2018. 37. 39. 5257-5268
Wang B, Li X, Zhao G, Yan H, Dong P, Watari H, Sims M, Li W, Pfeffer LM, Guo Y, et al. miR-203 inhibits ovarian tumor metastasis by targeting BIRC5 and attenuating the TGFβ pathway. Journal of experimental & clinical cancer research : CR. 2018. 37. 1. 235
Zeinab Mohamed, Mohamed Kamel Hassan, Safwat Okasha, Takashi Mitamura, Sarah Keshk, Yusuke Konno, Tatsuya Kato, Sherif F El-Khamisy, Yusuke Ohba, Hidemichi Watari. miR-363 confers taxane resistance in ovarian cancer by targeting the Hippo pathway member, LATS2. Oncotarget. 2018. 9. 53. 30053-30065
Satomi Aoyama-Kikawa, Hiromasa Fujita, Sharon J B Hanley, Mitsunori Kasamo, Kokichi Kikuchi, Toshihiko Torigoe, Yoshihiro Matsuno, Akiko Tamakoshi, Takayuki Sasaki, Motoki Matsuura, et al. Comparison of human papillomavirus genotyping and cytology triage, COMPACT Study: Design, methods and baseline results in 14 642 women. Cancer science. 2018. 109. 6. 2003-2012

ｍore...

MISC (419)：

ｍore...

Professional career (1)：

博士(医学) (北海道大学)

Work history (1)：

2010 - 2013 Hokkaido University

※ Researcher’s information displayed in J-GLOBAL is based on the information registered in researchmap. For details, see here.

Return to Previous Page